Get the Stockscreener App
12.35
3.14%
-0.40
After Hours:
12.36
0.010
+0.08%
Assembly Biosciences Inc stock is traded at $12.35, with a volume of 21,152.
It is down -3.14% in the last 24 hours and down -13.64% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two innovative platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.
See More
Previous Close:
$12.75
Open:
$12.7
24h Volume:
21,152
Relative Volume:
0.65
Market Cap:
$78.50M
Revenue:
-
Net Income/Loss:
$-61.23M
P/E Ratio:
-0.9135
EPS:
-13.5194
Net Cash Flow:
$22.49M
1W Performance:
-5.15%
1M Performance:
-13.64%
6M Performance:
-15.70%
1Y Performance:
+8.43%
1-Day Range:
$12.35
$13.04
1-Week Range:
$12.31
$13.75
52-Week Range:
$11.05
$19.93
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
12.35 | 78.50M | 0 | -61.23M | 22.49M | -13.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
(ASMB) Investment Analysis - Stock Traders Daily
Assembly Biosciences and Gilead's genital herpes treatment gives positive results in early stage trial - MSN
Assembly Bio advances herpes treatment into next trial phase By Investing.com - Investing.com Nigeria
Assembly Bio advances herpes treatment into next trial phase - Investing.com
Catalent Announces New Board Appointments - Business Wire
Can This New Once-Weekly Herpes Treatment Transform Patient Care? Phase 1a Results Reveal Breakthrough - StockTitan
Peapod Lane Capital LLC Takes $994,000 Position in Assembly Biosciences, Inc. (NASDAQ:ASMB) - MarketBeat
Biotechnology Market Size, Share, Trends Research Report 2025-2034 - PharmiWeb.com
JPMorgan Chase & Co. Boosts Holdings in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Reviewing Assembly Biosciences (NASDAQ:ASMB) and CytoDyn (OTCMKTS:CYDY) - Defense World
When the Price of (ASMB) Talks, People Listen - Stock Traders Daily
AC Immune (NASDAQ:ACIU) & Assembly Biosciences (NASDAQ:ASMB) Head-To-Head Review - Defense World
(ASMB) Technical Pivots with Risk Controls - Stock Traders Daily
Geode Capital Management LLC Has $712,000 Stock Position in Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Gilead raises Assembly Bio stake to ~30% - MSN
IGM Bio stock plunges as analysts downgrade (IGMS:NASDAQ) - Seeking Alpha
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data - Liver Disease News
Trend Tracker for (ASMB) - Stock Traders Daily
Assembly Biosciences (NASDAQ:ASMB) Share Price Passes Above 200 Day Moving AverageHere's What Happened - MarketBeat
Assembly Biosciences extends lease through 2029 By Investing.com - Investing.com Nigeria
Assembly Biosciences extends lease through 2029 - Investing.com India
Brokerages Set TKO Group Holdings, Inc. (NYSE:TKO) PT at $136.79 - Defense World
Financial Analysis: Assembly Biosciences (NASDAQ:ASMB) vs. LifeVantage (NASDAQ:LFVN) - Defense World
Assembly Biosciences director Houghton buys $49,997 in stock By Investing.com - Investing.com Australia
Assembly Biosciences director Houghton buys $49,997 in stock - Investing.com India
Assembly Biosciences, Inc. (NASDAQ:ASMB) Director Acquires $49,983.22 in Stock - MarketBeat
Gilead Buys $20.1 Million of Assembly Biosciences Stock - MSN
Assembly Biosciences, Inc. (NASDAQ:ASMB) Sees Large Drop in Short Interest - MarketBeat
(ASMB) Long Term Investment Analysis - Stock Traders Daily
Assembly Biosciences’ (ASMB) “Neutral” Rating Reaffirmed at HC Wainwright - Defense World
H.C. Wainwright maintains Neutral on Assembly Biosciences stock By Investing.com - Investing.com Canada
Assembly Biosciences' (ASMB) Neutral Rating Reiterated at HC Wainwright - MarketBeat
Assembly Biosciences Shares Rise on Results from Hepatitis B Drug Trial - MarketWatch
Assembly Bio stock spikes on Gilead-partnered drug (ASMB:NASDAQ) - Seeking Alpha
Assembly Biosciences reports positive phase 1b HBV drug results - Investing.com
Assembly Biosciences Reports Interim Phase 1b Results from Clinical Trial Evaluating Next-Generation Capsid Assembly Modulator Candidate ABI-4334 in Chronic Hepatitis B - The Manila Times
Assembly Bio's ABI-4334 Shows Strong HBV Antiviral Activity in Phase 1b Trial2.9 Log DNA Reduction - StockTitan
Gilead Sciences invests $20.1 million in Assembly Biosciences By Investing.com - Investing.com India
Fmr LLC Purchases 3,635 Shares of Assembly Biosciences, Inc. (NASDAQ:ASMB) - Defense World
Assembly Biosciences (NASDAQ:ASMB) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World
Assembly Biosciences (NASDAQ:ASMB) Shares Pass Above 200 Day Moving AverageHere's Why - MarketBeat
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
Assembly Biosciences Inc Stock (ASMB) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 10% Owner |
Dec 19 '24 |
Buy |
21.37 |
940,499 |
20,098,464 |
2,209,471 |
| Schornstein Alexander | 10% Owner |
Nov 22 '24 |
Buy |
14.87 |
17,024 |
253,104 |
720,137 |
| Schornstein Alexander | 10% Owner |
Nov 25 '24 |
Buy |
14.91 |
7,976 |
118,890 |
728,113 |
| White Nicole S | Chief Manufacturing Officer |
Nov 18 '24 |
Sale |
16.29 |
40 |
652 |
11,871 |
| Schornstein Alexander | 10% Owner |
Oct 08 '24 |
Buy |
14.58 |
10,000 |
145,800 |
703,113 |
| White Nicole S | Chief Manufacturing Officer |
Oct 03 '24 |
Sale |
14.81 |
157 |
2,325 |
11,911 |
| Okazaki Jason A | CEO and President |
Oct 03 '24 |
Sale |
14.81 |
197 |
2,918 |
14,904 |
| White Nicole S | Chief Manufacturing Officer |
Aug 02 '24 |
Sale |
14.23 |
785 |
11,173 |
12,068 |
| Okazaki Jason A | CEO and President |
Aug 02 '24 |
Sale |
14.23 |
981 |
13,962 |
15,101 |
| Schornstein Alexander | 10% Owner |
Jul 03 '24 |
Buy |
12.29 |
4,562 |
56,067 |
688,675 |
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):